Kaken Pharmaceutical Co., Ltd. (TYO:4521)
4,786.00
-37.00 (-0.77%)
Mar 13, 2025, 3:30 PM JST
Kaken Pharmaceutical Cash Flow Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 - 2015 |
Net Income | - | 9,796 | 6,817 | 13,885 | 18,657 | 26,592 | Upgrade
|
Depreciation & Amortization | - | 2,753 | 2,568 | 2,486 | 2,318 | 2,761 | Upgrade
|
Loss (Gain) From Sale of Assets | - | 167 | 1,911 | 2,896 | -333 | 348 | Upgrade
|
Loss (Gain) From Sale of Investments | - | -13 | -1 | -1 | -115 | - | Upgrade
|
Other Operating Activities | - | -3,788 | -4,407 | -4,431 | -5,517 | -7,807 | Upgrade
|
Change in Accounts Receivable | - | -4,559 | 972 | 392 | 1,251 | 8,539 | Upgrade
|
Change in Inventory | - | -1,603 | -583 | 241 | -2,923 | 1,446 | Upgrade
|
Change in Accounts Payable | - | 880 | 280 | -2,630 | -112 | -3,576 | Upgrade
|
Change in Other Net Operating Assets | - | -1,056 | 1,696 | 498 | 1,154 | -835 | Upgrade
|
Operating Cash Flow | - | 2,577 | 9,253 | 13,336 | 14,380 | 27,468 | Upgrade
|
Operating Cash Flow Growth | - | -72.15% | -30.62% | -7.26% | -47.65% | 30.00% | Upgrade
|
Capital Expenditures | - | -1,861 | -1,987 | -2,986 | -1,973 | -2,159 | Upgrade
|
Sale of Property, Plant & Equipment | - | 1 | 12 | 704 | 874 | - | Upgrade
|
Cash Acquisitions | - | - | - | -4,975 | - | - | Upgrade
|
Sale (Purchase) of Intangibles | - | -306 | -219 | -271 | -313 | -43 | Upgrade
|
Investment in Securities | - | 516 | -195 | 5 | 124 | - | Upgrade
|
Other Investing Activities | - | -4,204 | -238 | -365 | -356 | -326 | Upgrade
|
Investing Cash Flow | - | -5,854 | -2,627 | -7,888 | -1,644 | -2,528 | Upgrade
|
Short-Term Debt Repaid | - | - | - | - | - | -25 | Upgrade
|
Total Debt Repaid | - | - | - | - | - | -25 | Upgrade
|
Net Debt Issued (Repaid) | - | - | - | - | - | -25 | Upgrade
|
Repurchase of Common Stock | - | - | -1,340 | -2,414 | -2,940 | -4,252 | Upgrade
|
Dividends Paid | - | -5,657 | -5,649 | -5,714 | -5,811 | -5,896 | Upgrade
|
Other Financing Activities | - | -1 | -1 | -1 | -1 | - | Upgrade
|
Financing Cash Flow | - | -5,658 | -6,990 | -8,129 | -8,752 | -10,173 | Upgrade
|
Miscellaneous Cash Flow Adjustments | - | - | - | 1 | -1 | -1 | Upgrade
|
Net Cash Flow | - | -8,935 | -364 | -2,680 | 3,983 | 14,766 | Upgrade
|
Free Cash Flow | - | 716 | 7,266 | 10,350 | 12,407 | 25,309 | Upgrade
|
Free Cash Flow Growth | - | -90.15% | -29.80% | -16.58% | -50.98% | 31.67% | Upgrade
|
Free Cash Flow Margin | - | 0.99% | 9.96% | 13.61% | 16.55% | 28.36% | Upgrade
|
Free Cash Flow Per Share | - | 18.97 | 193.39 | 272.53 | 321.51 | 646.63 | Upgrade
|
Cash Interest Paid | - | 17 | 17 | 17 | 17 | 17 | Upgrade
|
Cash Income Tax Paid | - | 3,788 | 4,409 | 4,431 | 5,516 | 7,807 | Upgrade
|
Levered Free Cash Flow | - | -1,299 | 7,486 | 8,025 | 9,418 | 21,379 | Upgrade
|
Unlevered Free Cash Flow | - | -1,289 | 7,497 | 8,036 | 9,429 | 21,390 | Upgrade
|
Change in Net Working Capital | -5,522 | 7,821 | -2,135 | 1,859 | 1,721 | -4,261 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.